Related Experiment Video
Updated: Jul 18, 2025
Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling
Published on: June 25, 2015
TET protein inhibitors: Potential and limitations
Robert Kaplánek1, Zdeněk Kejík1, Jan Hajduch1
1BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.
This review explores Ten-Eleven Translocation (TET) protein inhibitors for cancer therapy. It details their mechanisms, applications, and limitations, offering insights into novel therapeutic strategies for oncological diseases.
Area of Science:
- Biochemistry and Molecular Biology
- Epigenetics
- Oncology
Background:
- Ten-Eleven Translocation (TET) proteins are crucial regulators of gene expression through DNA demethylation.
- Aberrant TET protein activity is implicated in the pathogenesis of various cancers.
- Targeting TET proteins with inhibitors presents a potential therapeutic avenue for oncological diseases.
Purpose of the Study:
- To review and categorize different types of TET protein inhibitors.
- To analyze the inhibitory mechanisms and potential applications of these compounds.
- To evaluate the therapeutic strategies and limitations of TET inhibition in cancer treatment.
Main Methods:
- Literature review of existing studies on TET protein inhibitors.
- Analysis of inhibitory mechanisms, including competitive and allosteric inhibition.
- Evaluation of preclinical and clinical data regarding TET inhibitor efficacy and safety.
Main Results:
- Various classes of TET inhibitors have been identified, differing in their molecular targets and modes of action.
- Inhibitors show promise in preclinical cancer models by modulating epigenetic landscapes.
- Challenges include achieving specificity, managing off-target effects, and understanding complex in vivo functionality.
Conclusions:
- TET protein inhibitors offer a promising, albeit complex, strategy for cancer therapy.
- Further research is needed to optimize inhibitor design and fully elucidate their therapeutic potential and limitations.
- Targeted inhibition of TET proteins could lead to novel epigenetic therapies for various cancers.
